Using a combination of X-ray crystallography and biochemical approaches, the authors have characterized a plasmid-encoded Type II-A CRISPR-Cas system inhibitor, namely AcrIIA19, that exhibits broad-spectrum inhibition across divergent Cas9 orthologs. This work also identifies the WED domain as a strategic target for developing species-agnostic CRISPR regulatory tools for biotechnology and therapeutic applications.
- Gi Eob Kim
- So Yeon Lee
- Hyun Ho Park